title: Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats.
abstract: The α7 nicotinic acetylcholine receptor (nAChR) is a potential target for the treatment of cognitive deficits in patients with schizophrenia, ADHD and Alzheimer's disease. Here we test the hypothesis that upregulation of α7 nAChR levels underlies the enhanced and sustained procognitive effect of repeated administration of α7 nAChR agonists. We further compare the effect of agonists to that of α7 nAChR positive allosteric modulators (PAMs), which do not induce upregulation of the α7 nAChR. Using the social discrimination test as a measure of short-term memory, we show that the α7 nAChR agonist A-582941 improves short-term memory immediately after repeated (7× daily), but not a single administration. The α7 nAChR PAMs PNU-120596 and AVL-3288 do not affect short-term memory immediately after a single or repeated administration. This demonstrates a fundamental difference in the behavioral effects of agonists and PAMs that may be relevant for clinical development. Importantly, A-582941 and AVL-3288 increase short-term memory 24 hrs after repeated, but not a single, administration, suggesting that repeated administration of both agonists and PAMs may produce sustained effects on cognitive performance. Subsequent [(125)I]-bungarotoxin autoradiography revealed no direct correlation between α7 nAChR levels in frontal cortical or hippocampal brain regions and short-term memory with either compound. Additionally, repeated treatment with A-582941 did not affect mRNA expression of RIC-3 or the lynx-like gene products lynx1, lynx2, PSCA, or Ly6H, which are known to affect nAChR function. In conclusion, both α7 nAChR agonists and PAMs exhibit sustained pro-cognitive effects after repeated administration, and altered levels of the α7 nAChR per se, or that of endogenous regulators of nAChR function, are likely not the major cause of this effect.
authors.affiliation: Neurobiology Research Unit, University Hospital Copenhagen, Copenhagen, Denmark. morten.s.thomsen@nru.dk
authors.forename: Morten S
authors.initials: MS
authors.lastname: Thomsen
authors.forename: Mona
authors.initials: M
authors.lastname: El-Sayed
authors.forename: Jens D
authors.initials: JD
authors.lastname: Mikkelsen
mesh_terms: D000818:Animals; D058851:GPI-Linked Proteins / Q000378:metabolism; D017403:In Situ Hybridization; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D007555:Isoxazoles / Q000494:pharmacology; D008297:Male; D008568:Memory / Q000187:drug effects*; D008570:Memory, Short-Term / Q000187:drug effects; D018722:Nicotinic Agonists / Q000494:pharmacology*; D018733:Nicotinic Antagonists / Q000494:pharmacology*; D010671:Phenylurea Compounds / Q000494:pharmacology; D011724:Pyridazines / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D011978:Receptors, Nicotinic / Q000378:metabolism*; D064569:alpha7 Nicotinic Acetylcholine Receptor
chemical_list: C508388:1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea; C524029:A-582941; C579165:Chrna7 protein, rat; D058851:GPI-Linked Proteins; D047908:Intracellular Signaling Peptides and Proteins; D007555:Isoxazoles; D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; D010671:Phenylurea Compounds; D011724:Pyridazines; D011758:Pyrroles; D012333:RNA, Messenger; D011978:Receptors, Nicotinic; D064569:alpha7 Nicotinic Acetylcholine Receptor
references.citation: Curr Drug Targets. 2012 May;13(5):707-20
references.pmid: 22300038
references.citation: Brain Res. 1996 May 13;720(1-2):111-9
references.pmid: 8782903
references.citation: Psychopharmacology (Berl). 1996 Apr;124(4):323-31
references.pmid: 8739547
references.citation: Behav Brain Res. 2005 Jul 1;162(1):143-52
references.pmid: 15922075
references.citation: J Pharmacol Exp Ther. 2009 Mar;328(3):766-76
references.pmid: 19050173
references.citation: Nat Protoc. 2008;3(6):1101-8
references.pmid: 18546601
references.citation: Clin Neuropharmacol. 2008 Jan-Feb;31(1):34-9
references.pmid: 18303489
references.citation: Eur Neuropsychopharmacol. 2007 Jan 15;17(2):145-55
references.pmid: 16650968
references.citation: Pharmacol Biochem Behav. 1997 May-Jun;57(1-2):231-41
references.pmid: 9164577
references.citation: Biochem Pharmacol. 2011 Dec 1;82(11):1521-7
references.pmid: 21787757
references.citation: J Neurochem. 2010 Aug;114(4):1205-16
references.pmid: 20533993
references.citation: Neuron. 2011 Apr 14;70(1):20-33
references.pmid: 21482353
references.citation: Neuroscience. 2003;121(4):975-82
references.pmid: 14580947
references.citation: Curr Top Med Chem. 2010;10(2):144-52
references.pmid: 20166959
references.citation: Br J Pharmacol. 2008 Mar;153 Suppl 1:S177-83
references.pmid: 18246096
references.citation: Neuropsychopharmacology. 2007 Jan;32(1):17-34
references.pmid: 16936709
references.citation: J Neurosci. 2007 Sep 26;27(39):10578-87
references.pmid: 17898229
references.citation: Biotechnol J. 2008 Dec;3(12):1539-47
references.pmid: 18956371
references.citation: Psychopharmacology (Berl). 1998 Apr;136(4):320-7
references.pmid: 9600576
references.citation: J Med Chem. 2008 Feb 28;51(4):701-12
references.pmid: 18198823
references.citation: Mol Pharmacol. 2007 Sep;72(3):715-24
references.pmid: 17565004
references.citation: Eur J Pharmacol. 2000 Mar 30;393(1-3):31-8
references.pmid: 10770995
references.citation: Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1261-5
references.pmid: 1741378
references.citation: J Neurosci. 2005 Apr 27;25(17):4396-405
references.pmid: 15858066
references.citation: Trends Pharmacol Sci. 2005 Jul;26(7):352-60
references.pmid: 15946748
references.citation: Neuropsychopharmacology. 2008 Nov;33(12):2820-30
references.pmid: 18256594
references.citation: Physiol Behav. 1995 Aug;58(2):315-21
references.pmid: 7568435
references.citation: Proc Natl Acad Sci U S A. 2007 May 8;104(19):8059-64
references.pmid: 17470817
references.citation: Curr Pharm Des. 2010 Jan;16(3):323-43
references.pmid: 20109142
references.citation: Behav Pharmacol. 1999 Nov;10(6-7):675-80
references.pmid: 10780509
references.citation: Neuroscience. 2011 Jul 14;186:76-87
references.pmid: 21550383
references.citation: J Pharmacol Exp Ther. 2011 Feb;336(2):560-74
references.pmid: 21084390
references.citation: Biochem Pharmacol. 2009 Oct 1;78(7):803-12
references.pmid: 19482012
references.citation: Learn Mem. 2004 Jan-Feb;11(1):21-7
references.pmid: 14747513
references.citation: J Pharmacol Exp Ther. 2007 Oct;323(1):294-307
references.pmid: 17625074
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4477-82
references.pmid: 19246390
references.citation: Biol Psychiatry. 2008 Jan 1;63(1):92-7
references.pmid: 17601496
references.citation: Biol Psychiatry. 2011 Jan 1;69(1):12-8
references.pmid: 20965497
references.citation: J Pharmacol Exp Ther. 2009 May;329(2):791-807
references.pmid: 19223664